295 results about "Lactate dehydrogenase" patented technology

A method for isolating succinic acid producing bacteria is provided comprising increasing the biomass of an organism which lacks the ability to catabolize pyruvate, and then subjecting the biomass to glucose-rich medium in an anaerobic environment to enable pyruvate-catabolizing mutants to grow.The invention also provides for a mutant that produces high amounts of succinic acid, which has been derived from a parent which lacked the genes for pyruvate formate lyase and lactate dehydrogenase, and which belongs to the E.coli Group of Bacteria.

A yeast strain, wherein the yeast strain is transformed with at least one copy of a gene coding for <SMALLCAPS>D</SMALLCAPS>-lactate dehydrogenase functionally linked to a promoter sequence allowing the expression of the gene in the yeast strain and the yeast strain has undergone disruption of one or more pyruvate decarboxylase genes or pyruvate dehydrogenase genes. Also, a method of producing <SMALLCAPS>D</SMALLCAPS>-lactic acid including culturing such a yeast strain in a medium and recovering <SMALLCAPS>D</SMALLCAPS>-lactic acid.

The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK.

A high flux of metabolites from pyruvate to 2,3-butanediol in Lactobacillus plantarum was achieved through genetic engineering. Substantial elimination of lactate dehydrogenase activity in the presence of heterologously expressed butanediol dehydrogenase activity led to 2,3 butanediol production that was at least 49% of the total of major pyruvate-derived products.

The present invention relates to a testing system for assessing hypoxia induced cellular damage in a mammal including human, comprising a disposable device having a sample inlet and a collection chamber separated by a separation device wherein the collection chamber is connected to at least two, a first and a second, visible detection compartments, whereof at least one is arranged with chemical means for direct visual detection, said first detection compartment being arranged to determine whether level of hemoglobin (Hb) in a sample of body fluid taken from said mammal exceeds a predetermined threshold value, and said second detection compartment being arranged to evaluate level of total amount of lactate dehydrogenase (LDH) in said sample.

Succinic acid is produced by allowing a bacterium modified to enhance fumarate reductase activity or cell preparation thereof to react with an organic raw material in a reaction solution containing one of a carbonate ion, a bicarbonate ion, and carbon dioxide gas to generate succinic acid. More preferably, succinic acid is produced by allowing a bacterium modified to enhance activities of fumarate reductase and pyruvate carboxylase and decrease lactate dehydrogenase activity or cell preparation thereof to react with an organic raw material in a reaction solution containing one of a carbonate ion, a bicarbonate ion, and carbon dioxide gas to generate succinic acid. Succinic acid is obtained by collecting the produced succinic acid.

The invention relates to a method for determining the content of blood ammonia, and also the reagent kit for blood ammonia diagnosis. The reagent kit comprises cushioning solution, adenosine triphosphate, phosphoenolpyruvate phosphatase, deacidized type coenzyme, ammonia kinase, pyruvate kinase, lactate dehydrogenase, and stabilizer. By mixing sample and reagent of a predetermiend volumetric ratio, generating coupling reaction between them, subjecting the final reactant to biochemiscal analyser, the main wavelength absorbancy variance ratio (speed) can be detected, and the blood ammonia content can thus be measured. The method of the invention can be used to obtain the needed measurement result purely through biochemical analytic instruments, and advantages of the method include higher sensibility, better accuracy, less susceptibility to contamination of internal or external materials, and easy application.

The invention relates to a liquid double reagent diagnostic reagent kit for determining the content of potassium ions in serum and blood plasma. By using the reaction principle that phosphoenolpyruvic acid (PEP) can be catalyzed by K+dependency pyruvate kinase (PK) to be converted into pyruvic acid and taking lactate dehydrogenase (LDH) as indicator enzyme by means of NADH, the reagent kit detects the reduction amount of the NADH at 340 nm and obtains the result that the change of the absorbance every minute (delta/min) is directly proportional to the content of K+, thereby establishing an enzyme coupling method for continuously determining the potassium ions. In addition, enzyme and a primer system required by slowly generating reduction type nicotinoyl coenzyme are added in a system andan enzyme-primer-coenzyme slow reaction system is formed in a reagent, so that the coenzyme can be slowly and circularly supplemented and the reagent can be stabilized when the concentration reaches a certain balance. The liquid double reagent diagnostic reagent kit is convenient and concise to use, carries out rapid detection on a common ultraviolet/visible light analyzer or a semiautomatic/fully-automatic chemical analyzer, needs no special or extra instrument and has low cost.

The invention provides a genetically engineered bacterium for high-yielding L-valine. A construction method of the genetically engineered bacterium comprises the steps that starting from an escherichia coli W3110, an acetolactate synthase gene alsS of a bacillus subtilis is integrated on a genome of the escherichia coli W3110 and subjected to high expression; an escherichia coli ppGpp 3'-pyrophosphoric acid hydrolytic enzyme mutant R290E/K292D gene spoT is integrated on the genome of the escherichia coli W3110 and subjected to high expression; genes of frdA, frdB, frdC and frdD of four subunits of a lactic dehydrogenase gene ldhA, a pyruvate formate lyase I gene pflB and fumaric reductase on the genome of the escherichia coli W3110 are knocked out; a branched chain amino acid transaminasegene ilvE of the escherichia coli is replaced with leucine dehydrogenase gene bcd of the bacillus subtilis; and an acetyl-hydroxyl acid isomerized reductase gene ilvC of the escherichia coli is replaced with an encoding gene of a mutant L67E/R68F/K75E. According to the genetically engineered bacterium for the high-yielding L-valine, an L-valine fermentation method is further modified. Double-phasedissolved oxygen control is adopted, and the L-valine yield and the saccharic acid conversion rate are improved.

The invention discloses an immunity-chromatography kit for the rapid diagnosis of malaria and its pathogen species and a preparation method thereof. The kit comprises a colloidal gold immunity-chromatography test strip, a matching cell-free lysate, a sample cup, a blood taking needle, and an operating instruction. The colloidal gold immunity-chromatography test strip comprises a sample pad, a colloidal-gold pad, a cellulose membrane, and a water-absorbing pad, wherein the colloidal-gold pad contains colloidal gold labelled antibodies; a detection line and a quality control line are disposed on the cellulose membrane; and the colloidal gold labelled antibody and the detection line are composed of monoclonal antibodies which can specifically bind the lactate dehydrogenase of plasmodia. The immunity-chromatography kit for the rapid diagnosis of malaria and its pathogen of the invention can distinguish falciparum malaria from vivax malaria, has the advantages of simplicity, sensitivity, specificity, and rapidity, and is suitable for clinical and field applications.

Disclosed herein are glucose tolerant C₂ carbon source-independent (GCSI) yeast strains having no detectable amount of pyruvate decarboxylase activity, wherein wild type yeast strains for the glucose tolerant C₂ carbon source-independent yeast strains are Crabtree positive. Also disclosed are methods of selecting glucose tolerant C₂ carbon source-dependent yeast strains, and methods of producing pyruvic acid or salts thereof using glucose tolerant C₂ carbon source-independent yeast strain. Further disclosed herein are GCSI yeast strains having a genome that comprises an exogenous lactate dehydrogenase gene.

The present invention relates to a transformant, containing a lactate dehydrogenase gene which is introduced into Schizosaccharomyces pombe as a host, in which a part of a gene cluster encoding a pyruvate decarboxylase in the Schizosaccharomyces pombe host is deleted or inactivated.

Genetically modified microorganisms having the ability to produce D(−)-lactic acid at temperatures between 30° C. and 55° C. are provided. In various embodiments, the microorganisms may have the chromosomal lactate dehydrogenase (ldh) gene and/or the chromosomal acetolactate synthase (alsS) gene inactivated. Exemplary microorganisms for use in the disclosed methods are Bacillus spp., such as Bacillus coagulans.

Modified microorganisms are prepared by inactivation of the endogenous lactate dehydrogenase gene. The microorganisms are deposited under NCIMB Accession Nos. 41277, 41278, 41279, 41280 or 41281.

The invention discloses a gene engineering bacterium for high-yield hyaluronic acid and a construction method and application of the gene engineering bacteria, and belongs to the field of gene engineering and biochemical engineering. The gene engineering bacterium for high-yield hyaluronic acid is constructed through the steps that a lactate dehydrogenase gene in corynebacterium glutamicum is inactivated, and then a hyaluronan synthase gene is transferred into the corynebacterium glutamicum. According to the gene engineering bacterium for high-yield hyaluronic acid, a corynebacterium glutamicum host has no pathogenicity to both humans and animals and is a food-grade safe microorganism; and the recombinant corynebacterium glutamicum for high-yield hyaluronic acid is high in hyaluronic acid yield which is up to 22g/L or above and three times the level of existing industrial production, and a new bacterial strain has good industrialization application prospects.

A mutated thermophilic microorganism is prepared, with a modification to inactivate the lactate dehydrogenase gene of a wild-type microorganism. The mutated microorganism is used in the production of ethanol, utilising C₃, C₅ or C₆ sugars as the substrate.

The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.

The present invention relates to a method of isolating hematopoietic stem cells from adipose tissue. The method yields a notably high number of CD34⁺, ALDH^br and/or ABCG2-expressing cells, comprising hematopoietic stem cells, permitting the use of the cells with no or minimal expansion.